Pancold A elicits FDA warning
This article was originally published in The Tan Sheet
Executive Summary
B&A Health Products' multi-symptom relief liquid OTC is an unapproved new drug because it does not conform with the final monograph for Cold, Cough, Allergy, Bronchodilator and Antiasthmatic Drug Products. The agency says Pancold A does not satisfy monograph requirements because it includes noncompliant ingredients, such as anhydrous caffeine and di-methylephedrine hydrochloride, according to an Aug. 19 letter to the Santa Fe Spring, Calif., firm. FDA also says several indications contravene the monograph, including a claim the product is a "sneeze suppressant." Finally, FDA warns, the drug's packaging does not bear the Drug Facts labeling required of OTC drugs
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.